Skip to main content

Find Clinical Trials

Home
Conditions
Neuroendocrine Tumors

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,767 public trials 494 recruiting studies

Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Active, Not Recruiting

Circulating Tumor DNA in Melanoma Patients

NCT07422805

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations: Institute of Oncology Ljubljana Ljubljana, Slovenia

View Trial Details

Active, Not Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

NCT05068102

Conditions: Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +24 more
Locations: VU University Medical Center Amsterdam, Netherlands

View Trial Details

Active, Not Recruiting

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

NCT06880549

Conditions: Advanced Solid Tumors, Disease Attributes, Melanoma, +16 more
Locations: START Midwest Grand Rapids, Michigan, United States

START San Antonio San Antonio, Texas, United States

START Mountain Region West Valley City, Utah, United States

View Trial Details

Active, Not Recruiting

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379

Conditions: Choroidal Melanoma, Eye Diseases, Eye Neoplasms, +13 more
Locations: Retina Associates SW, P.C. Tucson, Arizona, United States

UCLA Jules Stein Eye Institute Los Angeles, California, United States

Byers Eye Institute at Stanford University Palo Alto, California, United States

Retina Consultants of Sacramento Sacramento, California, United States

View all 16 locations

View Trial Details

Active, Not Recruiting

War on Melanoma™ Public Health & Education Campaign

NCT04611568

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Active, Not Recruiting

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108

Conditions: Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +23 more
Locations: LSU Health Sciences Center - Shreveport Shreveport, Louisiana, United States

Montefiore Medical Center The Bronx, New York, United States

University of North Carolina Chapel Hill, North Carolina, United States

UC Health Cincinnati, Ohio, United States

View Trial Details

Active, Not Recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716

Conditions: Advanced Melanoma, Melanoma, Neoplasms, +17 more
Locations: University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States

CTCA at Western Regional Medical Center Goodyear, Arizona, United States

Los Angeles General Medical Center Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center Los Angeles, California, United States

View all 20 locations

View Trial Details

Active, Not Recruiting

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

NCT04759911

Conditions: Adenocarcinoma, Adenocarcinoma, Papillary, Carcinoma, +25 more
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States

University of Michigan Health Systems Ann Arbor, Michigan, United States

M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536

Conditions: Melanoma, Metastatic Melanoma, Neoplasms, +10 more
Locations: Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Survival Monitoring in Russian Cancer Registries

NCT06043947

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +48 more
Locations: N. N. Petrov Research Institute of oncology Saint Petersburg, Russia

View Trial Details